Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Underpinning the results was strong demand for AbbVie's Skyrizi, an injectable drug used as a treatment for plaque psoriasis ...

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...

It can be administered in-office or by self-injection after training. Developed in partnership with Germany’s Boehringer Ingelheim, Skyrizi was approved in Japan and Canada in the past few weeks.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Moderna, AbbVie, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that focus on developing and ...